This Phase 1 randomized “HIV Cure Study” is evaluating whether ImmunityBio’s investigational agent N-803 along or together with broadly neutralizing antibodies can control HIV following antiretroviral therapy.

Acceptance Requirements

Adult patients diagnosed with HIV-1 infection

Must have been on ART for at least 96 weeks prior to joining the trial